Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
OBJECTIVE
Increased activity of Sp family of transcription factors is a frequent and critical event in cancer development and progression. Genes governing tumor growth, invasion and angiogenesis are regulated by Sp factors, like Sp1, Sp3 or Sp4, and are frequently over-expressed in tumors. Targeting Sp factors has been explored as a therapeutic approach. Mithramycin (MTM) is a natural antibiotic that binds DNA and inhibit Sp1-dependent transcription. New analogues, named MTM-SDK and MTM-SK, were recently obtained by genetic engineering of the MTM biosynthetic pathway and have demonstrated improved transcriptional and antiproliferative activity in ovarian cancer cell lines in vitro. In the present study we evaluated the activity of the new compounds in human ovarian cancer xenografts.


METHODS
Expression of Sp1 and target proteins in ovarian cancer specimens and tumor xenografts was assessed by immunohistochemistry. Drug-induced silencing of Sp1-regulated genes in cells and tumor xenograft samples was assessed by quantitative RT-PCR. Toxicity and antitumor activity of the compounds were investigated in healthy and tumor-bearing immunocompromised mice, respectively.


RESULTS
Expression of Sp1 was frequently increased in human epithelial ovarian cancers. MTM-SDK and MTM-SK acted as potent inhibitors of Sp1-dependent transcription both in vitro and in tumor xenografts. Both compounds were well tolerated even after prolonged administration and delayed growth of ovarian tumor xenografts. MTM-SDK was particularly effective against orthotopic tumors leading to a significant increase of survival and delay of tumor progression.


CONCLUSIONS
MTM-SDK and MTM-SK show relevant activity in vivo and represent interesting candidates for treatment of ovarian cancers.
Previdi
Sara
S
Laboratory of Molecular Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy.
Malek
Anastasia
A
Albertini
Veronica
V
Riva
Cristina
C
Capella
Carlo
C
Broggini
Massimo
M
Carbone
Giuseppina M
GM
Rohr
Jurgen
J
Catapano
Carlo V
CV
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D048708:Cell Growth Processes / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008926:Plicamycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D016329:Sp1 Transcription Factor / Q000037:antagonists & inhibitors* / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D016329:Sp1 Transcription Factor; C520007:mithramycin SK; D008926:Plicamycin
Gynecol Oncol. 2007 Sep;106(3):526-37
17559911
J Am Chem Soc. 2003 May 14;125(19):5745-53
12733914
Nucleic Acids Res. 2007;35(7):2215-26
17369273
Cancer Res. 2005 Feb 1;65(3):1007-17
15705902
Cancer Res. 2000 Nov 15;60(22):6531-6
11103824
Biochem Biophys Res Commun. 2006 Jun 23;345(1):292-301
16678129
J Am Chem Soc. 2002 May 29;124(21):6056-62
12022840
Exp Oncol. 2007 Jun;29(2):121-5
17704744
Cancer Cell. 2004 Jan;5(1):19-24
14749123
Cancer Res. 2003 Mar 15;63(6):1235-41
12649182
Int J Gynecol Cancer. 2005 Sep-Oct;15(5):878-83
16174239
Biochemistry. 2003 Jul 15;42(27):8313-24
12846580
J Biol Chem. 2002 Aug 9;277(32):28815-22
12052832
J Clin Invest. 1991 Nov;88(5):1613-21
1834700
J Am Chem Soc. 2002 Feb 27;124(8):1606-14
11853433
Gynecol Oncol. 2009 Nov;115(2):290-301
19717182
Nat Rev Cancer. 2009 Mar;9(3):167-81
19238149
J Natl Cancer Inst. 2006 Jun 21;98(12):855-68
16788159
Eur J Cancer. 2005 Nov;41(16):2438-48
16209919
J Biol Chem. 2006 Jul 28;281(30):21433-21444
16714763
J Biol Chem. 2008 May 16;283(20):13934-42
18353772
Cancer Res. 2005 Aug 15;65(16):7378-85
16103090
Int J Cancer. 2008 Mar 15;122(6):1430-4
18027851
J Am Chem Soc. 2005 Dec 21;127(50):17594-5
16351075
J Clin Oncol. 2006 Feb 20;24(6):988-94
16461779
Mol Cancer Ther. 2006 Nov;5(11):2737-46
17121920
Biochemistry. 1993 Jul 6;32(26):6588-604
8329387
Clin Cancer Res. 2008 May 15;14(10):3030-5
18483368
Nucleic Acids Res. 2006 Mar 29;34(6):1721-34
16571899
Biochemistry. 1991 Apr 30;30(17):4290-7
1827033
Nat Rev Cancer. 2009 Jun;9(6):415-28
19461667
Cancer Res. 2008 Jul 1;68(13):5345-54
18593936
Mol Ther. 2004 Dec;10(6):1032-42
15564135
Cancer Res. 2007 Mar 15;67(6):2816-23
17363604
Cancer Res. 2007 Apr 1;67(7):3286-94
17409437
J Clin Oncol. 2008 Feb 20;26(6):995-1005
18195328
N Engl J Med. 2004 Dec 9;351(24):2519-29
15590954
Appl Microbiol Biotechnol. 2006 Nov;73(1):1-14
17013601
Cancer Biol Ther. 2007 Nov;6(11):1733-42
17986852
Cancer Cell. 2002 Feb;1(1):53-62
12086888
Carcinogenesis. 2009 Jul;30(7):1193-201
19406933
N Engl J Med. 2006 Jan 5;354(1):34-43
16394300
Nat Rev Cancer. 2005 May;5(5):355-66
15864277